Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SGN-CD123A |
Synonyms | |
Therapy Description |
SGN-CD123A is an antibody-drug conjugate comprising a CD123-targeted antibody linked to pyrrolobenzodiazepine dimers, which delivers the DNA cross-linking agent agent to CD123-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 29142066). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGN-CD123A | SGNCD123A|SGN CD123A | SGN-CD123A is an antibody-drug conjugate comprising a CD123-targeted antibody linked to pyrrolobenzodiazepine dimers, which delivers the DNA cross-linking agent agent to CD123-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 29142066). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02848248 | Phase I | SGN-CD123A | A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia | Terminated | USA | 0 |